Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor

In this Phase II study (n=81), the combination of osimertinib plus bevacizumab did not prolong progression-free survival when compared to osimertinib monotherapy (median 9.4 months vs 13.5 months, respectively; adjusted HR 1.44; 80% CI 1.00-2.08; p=0.2).

Source:

JAMA Oncology